Dashboard
1
Strong Long Term Fundamental Strength with a 44.82% CAGR growth in Operating Profits
- Company has a low Debt to Equity ratio (avg) at times
2
Flat results in Jun 25
3
With ROE of 18.56%, it has a expensive valuation with a 10.30 Price to Book Value
4
Company is among the highest 1% of companies rated by MarketsMojo across all 4,000 stocks
Stock DNA
Pharmaceuticals & Biotechnology
SEK 37,226 Million (Mid Cap)
55.00
NA
0.00%
-0.85
18.99%
9.04
Revenue and Profits:
Net Sales:
676 Million
(Quarterly Results - Jun 2025)
Net Profit:
245 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-16.4%
0%
-16.4%
6 Months
16.49%
0%
16.49%
1 Year
8.05%
0%
8.05%
2 Years
27.8%
0%
27.8%
3 Years
125.71%
0%
125.71%
4 Years
290.69%
0%
290.69%
5 Years
234.44%
0%
234.44%
Camurus AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
54.73%
EBIT Growth (5y)
44.82%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.82
Sales to Capital Employed (avg)
0.73
Tax Ratio
22.81%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
53.15%
ROE (avg)
8.72%
Valuation key factors
Factor
Value
P/E Ratio
55
Industry P/E
Price to Book Value
10.30
EV to EBIT
43.28
EV to EBITDA
42.32
EV to Capital Employed
67.36
EV to Sales
16.12
PEG Ratio
0.26
Dividend Yield
NA
ROCE (Latest)
155.65%
ROE (Latest)
18.56%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
675.50
558.30
20.99%
Operating Profit (PBDIT) excl Other Income
304.30
235.80
29.05%
Interest
1.40
1.30
7.69%
Exceptional Items
0.00
0.00
Consolidate Net Profit
244.80
197.30
24.08%
Operating Profit Margin (Excl OI)
441.20%
412.30%
2.89%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 20.99% vs 0.94% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 24.08% vs 34.22% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,867.60
1,716.90
8.78%
Operating Profit (PBDIT) excl Other Income
483.60
544.30
-11.15%
Interest
1.10
1.30
-15.38%
Exceptional Items
0.10
0.00
Consolidate Net Profit
428.40
431.40
-0.70%
Operating Profit Margin (Excl OI)
252.00%
310.10%
-5.81%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 8.78% vs 79.54% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -0.70% vs 675.90% in Dec 2023
About Camurus AB 
Camurus AB
Pharmaceuticals & Biotechnology
Camurus AB is a Sweden-based research and development based pharmaceutical company with a focus on the development and commercialization of specialty medicines, providing patients suffering from serious and chronic disease, such as opioid dependence, pain, cancer, acromegaly, and neuroendocrine tumors. The Company has a diversified research portfolio, which includes five products in clinical trials, and a number of additional product candidates in the pre-clinical phase. The Company’s product pipeline represents a mix of in-house and partnered projects in different development phases. Camurus AB is the parent company of the Group, which comprises four legal entities, namely Camurus Inc, Cubosome Inc, Camurus Development AB and Bioimplant Scandinavia AB.
Company Coordinates 
Company Details
Solvegatan 41 , LUND None : 223 62
Registrar Details






